A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Exclusion Criteria

• •First relapsed participants aged less than (\<) 60 years with first CR duration greater than (\>) 1 year
• •Participants with prior documented antecedent hematological disorder (AHD)
• •AML secondary to any prior chemotherapy unrelated to leukemia
• •Participants who are either refractory to or relapsed within 90 days of receiving a regimen containing a cumulative dose of greater than or equal to (\>/=) 18 g/m\^2 of cytarabine
• •Participants who have received allogeneic HSCT within 90 days prior to randomization
• •Participants who have received immunosuppressive therapy for graft versus host disease or for engraftment syndrome after autologous stem cell transplantation within 2 weeks prior to randomization
• •Prior treatment with an Murine Double Minute 2 (MDM2) antagonist
• •Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 30 days from first receipt of study drug
• •Participants with a history of other malignancy within 5 years prior to screening except for malignancy that has been in remission without treatment for at least 2 years prior to randomization
• •Participants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• •Participants with extramedullary AML with no evidence of systemic involvement
• •Pregnant or breastfeeding participants